Key result
Electrographic flow-guided ablation evaluated for persistent AF after failed PVI.
Why the study?
To evaluate the reliability of electrographic flow mapping technology to identify active extra-pulmonary vein AF sources and guide ablation therapy in patients with persistent AF.
Does PVI plus ablation of EGF-identified extra-PV sources improve the elimination of significant sources of excitation compared to PVI only in patients with persistent AF who failed prior PVI?
RCT (n=85)
1:1
Yes
Does PVI plus ablation of EGF-identified extra-PV sources improve the elimination of significant sources of excitation compared to PVI only in patients with persistent AF who failed prior PVI?
The FLOW-AF trial is designed to evaluate whether electrographic flow-guided ablation of extra-pulmonary vein sources is safe and effective in patients with persistent atrial fibrillation and prior failed isolation.
No takes yet. Share an insight, caveat, or question.
Evaluates EGF-guided extra-PV ablation for redo persistent AF; extends PVI strategies with randomized evidence on source elimination.
Szili‐Törok et al. (2023) conducted an RCT in Persistent or long-standing persistent atrial fibrillation (n=85). PVI + ablation of EGF-identified extra-PV sources of AF vs. PVI only was evaluated on Freedom from serious adverse events related to the procedure through 7 days (safety); successful elimination of significant sources of excitation (effectiveness). The FLOW-AF trial is a randomized study designed to evaluate electrographic flow-guided ablation in 85 patients with persistent atrial fibrillation who failed prior pulmonary vein isolation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: